Testing mini-CHOP versus adding polatuzumab for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 80+ or considered frail at 75+ by a brief aging/health check your team will do
- You have a confirmed diagnosis of one of these lymphomas: diffuse large B-cell lymphoma (including some transformed types), follicular lymphoma grade 3B, T-cell/histiocyte-rich LBCL, primary cutaneous DLBCL leg type, EBV-positive DLBCL, primary mediastinal LBCL, or high-grade B-cell lymphoma with MYC/BCL2 changes
- Your lymphoma is stage II, III, or IV, and there is at least one measurable tumor area bigger than about 1.5 cm
- You have not had any prior treatment for your lymphoma
- You are able to do study tasks (a “performance status” score of 0 to 3, depending on your situation) and can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an extra targeted drug (called X) to the standard chemo (Pola-R-CHP) can help people with aggressive B-cell lymphoma that didn't respond well after the first round. It aims to improve outcomes for those who need a stronger treatment approach.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests if a new drug combination (R-CMOP) works as well as or better than the usual combination (R-CHOP) for people with a type of lymphoma called DLBCL who haven't had treatment yet.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.